Can Doximity's New AI Suite Drive the Growth It Needs?

Doximity (DOCS) reported stronger-than-expected Q1 revenues of $145.9 million, up 15% year-over-year, with an adjusted EBITDA margin of 55%, while strategically positioning artificial intelligence as its core growth driver. The company's new AI Scribe, a HIPAA-compliant note-taking tool, has achieved significant traction with 10,000 beta testers and 75% weekly usage, complemented by the $26 million acquisition of Pathway to enhance clinical AI capabilities. This AI suite aims to deeply integrate into physician workflows and reduce documentation burden, setting the stage for potential enterprise revenue models, though management forecasts 11% revenue growth for fiscal 2026 amid policy uncertainty.

Analysis

Doximity (DOCS) began fiscal 2026 with strong financial performance, reporting a 15% year-over-year revenue increase to $145.9 million and a robust adjusted EBITDA margin of 55%. This financial strength, further evidenced by a 52% rise in free cash flow and a net revenue retention rate of 118%, provides a solid foundation for its strategic pivot towards artificial intelligence, termed its "third act." The company's AI suite is centered on the AI Scribe, a HIPAA-compliant note-taking tool that has already gained significant early traction with 10,000 beta testers and 75% weekly engagement. Management's strategy is to prioritize user adoption by offering Scribe for free, aiming to replicate the successful freemium-to-enterprise monetization model of its Dialer product. The strategic $26 million acquisition of Pathway bolsters this initiative by integrating a proprietary medical corpus that scored 96% on the U.S. medical licensing exam, a critical factor for establishing physician trust and ensuring clinical accuracy. Despite these positive developments and strong current metrics, management projects a more moderate 11% revenue growth for the full fiscal year, citing caution around "policy-driven uncertainty." The central challenge remains converting high user adoption of its free AI tools into a durable, revenue-generating enterprise solution within a competitive landscape where peers like Certara and GE HealthCare are also aggressively pursuing AI-driven growth.

Key Decisions for Investors

• Investors should recognize the strong early adoption of AI Scribe as a key positive indicator of Doximity's product-market fit, but remain focused on future earnings calls for concrete evidence of the transition from a free adoption model to a revenue-generating enterprise contract pipeline.
• The discrepancy between the strong 15% Q1 revenue growth and the more cautious full-year guidance of 11% warrants attention; investors should monitor for any clarification on the 'policy-driven uncertainty' mentioned by management as a potential headwind.
• Doximity's powerful financial profile, including a 55% EBITDA margin and significant share repurchases, provides a substantial buffer and downside support, allowing the company to invest in its long-term AI strategy from a position of strength.
• Evaluate Doximity's progress relative to competitors like Certara, which is already reporting significant software revenue growth from its AI tools, to gauge Doximity's execution speed and ability to differentiate its offerings in the crowded healthcare AI space.